101723 633 AM Alnylam Pharmaceuticals Press Release  Aug 03 2022  Alnylam Reports Positive Topline Results from APOLLOB Phase 3 Study of Patisira httpsinvestorsalnylamcompressreleaseid26851 19 Alnylam Reports Positive Topline Results from APOLLOB Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Aug 03 2022  Patisiran Met the Primary Endpoint with a Statistically Significant Improvement in 6Minute Walk Test Compared to Placebo at 12 Months   Patisiran Also Met the First Secondary Endpoint with a Statistically Significant Improvement in Quality of Life as Measured by the Kansas City Cardiomyopathy Questionnaire Compared to Placebo at 12 Months  101723 633 AM Alnylam Pharmaceuticals Press Release  Aug 03 2022  Alnylam Reports Positive Topline Results from APOLLOB Phase 3 Study of Patisira httpsinvestorsalnylamcompressreleaseid26851 29 Patisiran Demonstrated Encouraging Safety and Tolerability Profile in Patients with ATTR Amyloidosis with Cardiomyopathy   Company Plans to File a Supplemental New Drug Application in US in Late 2022   Full Data Will Be Presented at the 18 International Symposium on Amyloidosis   Alnylam to Host Conference Call Today at 800 am ET  CAMBRIDGE MassBUSINESS WIREAug 3 2022 Alnylam Pharmaceuticals Inc httpsctsbusinesswirecomctCT